Ikatibant Fresenius

Icatibant Acetate, the active ingredient in Ikatibant Fresenius, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with a confirmed diagnosis.

GNH USA supplies Ikatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant Acetate is used to manage bradykinin‑mediated swelling disorders, particularly hereditary angioedema. - Hereditary angioedema (HAE) type I and II: Reduces swelling and shortens the duration of acute attacks. - Acute bradykinin‑mediated angioedema: Provides rapid symptom relief during sudden episodes. - HAE with C1‑esterase inhibitor deficiency: Restores normal vascular permeability during crises.

Icatibant Acetate may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: Discomfort at the site of subcutaneous administration. - Redness or erythema: Localized skin irritation. - Swelling at injection site: Mild to moderate edema. - Nausea: Transient gastrointestinal upset. - Headache: Mild to moderate intensity. - Dizziness: Transient sensation of light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: Rash, itching, or hives. - Anaphylaxis: Severe, potentially life‑threatening allergic response. - Severe hypotension: Marked drop in blood pressure. - Angioedema unrelated to HAE: Unexpected swelling in other areas. - Thrombocytopenia: Low platelet count. - Injection‑site infection: Signs of local infection such as warmth or pus.

Before using Icatibant Acetate, consider the following safety measures. - Renal impairment: Monitor renal function and adjust therapy as needed. - Hepatic impairment: Use with caution and observe liver function tests. - Pregnancy: Safety not established; weigh potential benefits against risks. - Concomitant ACE inhibitors or ARBs: May increase bradykinin levels; monitor for angioedema. - Known hypersensitivity: Discontinue immediately if allergic reaction occurs. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Icatibant Acetate can interact with other medications that influence the bradykinin pathway or cardiovascular system.

Major Interactions (Avoid): - ACE inhibitors: Heightened risk of angioedema. - Angiotensin receptor blockers (ARBs): May amplify bradykinin‑mediated effects. - Other bradykinin‑targeting agents: Additive blockade could cause unexpected reactions.

Moderate Interactions (Monitor Closely): - Diuretics: Observe blood pressure and electrolyte balance. - Antihistamines: May mask early signs of hypersensitivity. - NSAIDs: Monitor for increased swelling or pain at injection site.